Kailera Therapeutics, Inc. (NASDAQ:KLRA) Stock Has Average Price Target of $42.75 According to Brokerages

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA) have been given a consensus recommendation of “Moderate Buy” by the nine ratings firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $43.00.

Several analysts have commented on the stock. Canaccord Genuity Group initiated coverage on shares of Kailera Therapeutics in a research report on Monday. They issued a “buy” rating and a $44.00 price objective on the stock. Weiss Ratings raised shares of Kailera Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research report on Wednesday, October 21st.

Kailera Therapeutics Price Performance

KLRA stock opened at $13.70 on Tuesday. The stock’s fifty day simple moving average is $12.73 and its two-hundred day simple moving average is $17.65. Kailera Therapeutics has a 1-year low of $9.76 and a 1-year high of $28.23.

Kailera Therapeutics (NASDAQ:KLRA) last announced its earnings results on Wednesday, November 4th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.55) by $0.81. On average, equities research analysts forecast that Kailera Therapeutics will post -3.89 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kailera Therapeutics

Institutional investors have recently bought and sold shares of the company. Commonwealth Equity Services LLC purchased a new position in shares of Kailera Therapeutics during the 3rd quarter valued at $134,000. Tidal Investments LLC bought a new position in shares of Kailera Therapeutics during the 2nd quarter worth $309,000. Profund Advisors LLC purchased a new stake in Kailera Therapeutics in the 3rd quarter worth about $216,000. Alps Advisors Inc. increased its holdings in Kailera Therapeutics by 31.1% in the 3rd quarter. Alps Advisors Inc. now owns 171,739 shares of the company’s stock worth $1,961,000 after acquiring an additional 40,739 shares during the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in Kailera Therapeutics in the 2nd quarter worth about $993,000.

About Kailera Therapeutics

Kailera Therapeutics is a clinical-stage biopharmaceutical company developing medicines for obesity and related metabolic diseases. Its research focuses on treatments that act on biological pathways involved in appetite, weight regulation and metabolism.

The company’s pipeline includes investigational injectable and oral therapies, including programs designed to target GLP-1 and GIP receptors. These products are in development and are not approved for commercial use.

Founded in 2024, Kailera has secured development and commercialization rights outside Greater China to drug candidates discovered by Jiangsu Hengrui Pharmaceuticals.